Nippon India Pharma Fund - Direct Plan - Bonus Plan
Compare
Equity
Direct
Sector - Healthcare
NAV: ₹ 302.3 as on 27-01-2023
Fund Performance
Fund Performance as on (19-Jan-23)
About the Fund
Nippon India Pharma Fund - Direct Plan - Bonus Plan is an equity fund. This fund was started on 1 January, 2013. The fund is managed by Kinjal Desai, Sailesh Raj Bhan, Akshay Sharma. The fund could potentially beat inflation in the long-run.
Key parameters
1) Nippon India Pharma Fund - Direct Plan - Bonus Plan has a NAV of ₹302.2554 as on 27-01-2023.
2) Nippon India Pharma Fund - Direct Plan - Bonus Plan has ₹4563 Cr worth of assets under management (AUM) as on 30-11-2022 and is more than category average.
3) The fund has an expense ratio 1.11 %.
Fund Overview
Expense ratio | 1.11% |
Benchmark | S&P BSE Healthcare PR |
AUM | ₹4563 Cr |
Inception Date | 1 January, 2013 |
Min Lumpsum/SIP | ₹5000/₹0 |
Exit Load | 1% |
Lock In | No Lock-in |
TurnOver | 38.42% |
Fund Distribution as on (31-Dec-22)
Size breakup
Large cap
44.3%
Mid cap
32.2%
Small cap
23.1%
Sector Allocation
Health
100%
Top Holdings as on (31-Dec-22)
Equity Holdings31
Debt Holdings3
Holdings | Weight% | Holdings Trend | 1M Change |
|---|---|---|---|
Sun Pharmaceuticals Industries Ltd | 14.39% | -6.4% | |
Dr Reddy's Laboratories Ltd | 8.22% | 0% | |
Cipla Ltd | 8.02% | -8.1% | |
Lupin Ltd | 7.24% | 0% | |
Abbott India Ltd | 6.06% | 0% |
See all
What changed
in last one month
AUM decreased by 223.5 Cr in last 1M
Dec'22 return underperformed benchmark
Change in AUM
Dec'22
₹ 4.6K Cr
Nov'22
₹ 4.8K Cr
Oct'22
₹ 4.8K Cr
Fund Returns vs Benchmark
Dec'22
2.78%
5.37%
Nov'22
0.96%
2.63%
Oct'22
2.78%
5.37%
Fund Return
Benchmark Return
Concentration Analysis as on (31-Dec-22)
Winners & Losers as on (31-Dec-22)
Top Growth Drivers | 1M Return |
|---|---|
Abbott India Ltd | 3.9% |
Sanofi India Ltd | 2.9% |
Zydus Lifesciences Ltd | 2.1% |
Peer Analysis
Fund Manager
Kinjal Desai
Fund Manager of Nippon India Pharma Fund - Direct Plan - Bonus Plan, since 25 May 2018
Top funds managed
Sailesh Raj Bhan
Fund Manager of Nippon India Pharma Fund - Direct Plan - Bonus Plan, since 1 April 2005
Top funds managed
Akshay Sharma
Fund Manager of Nippon India Pharma Fund - Direct Plan - Bonus Plan, since 1 December 2022
Top funds managed
AMC details
Fund House
Nippon Life India Asset Management Ltd
Total Schemes
Total AUM
₹2.28L Cr
as on 31-Dec-2022
Address
Nippon Life India Asset Management Limited,4th Floor, Tower A, Peninsula Business Park,,Ganapatrao Kadam Marg,,Lower Parel (W)
Phone
022-68087000/18602660111
Email
customercare@nipponindiaim.in
Fund Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 15.67% since inception which is more than its category average return of 15.5%
Fund Allocations
This fund has an allocation of 99.55% in Equity, 0% in Debt and 0.45% in Cash related instruments
AUM size ₹4563 Cr
This fund has AUM of ₹4563 Cr which is more than its category average of ₹ 1318 Cr
Expense Ratio 1.11%
This fund has an expense ratio of 1.11% which is less than its category average expense ratio of 1.54%
Frequently Asked Questions
The current NAV of Nippon India Pharma Fund - Direct Plan - Bonus Plan is 302.26 as on 27-Jan-2023.
Existing (Absolute + CAGR)
Nippon India Pharma Fund - Direct Plan - Bonus Plan | Absolute Returns | CAGR Returns |
1 Month Returns | -2.95% | -2.95% |
6 Month Returns | 2.93% | 2.93% |
1 Year Returns | -2.6% | -2.6% |
3 Years Returns | 81.81% | 22.05% |
5 Years Returns | 96.73% | 14.49% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
1.11 as on December 2022
4563 Cr as on December 2022
Sun Pharmaceuticals Industries Ltd(14.39%),Dr Reddy's Laboratories Ltd(8.22%),Cipla Ltd(8.02%),Lupin Ltd(7.24%),Abbott India Ltd(6.06%) as on December 2022
The alpha ratio for the Nippon India Pharma Fund - Direct Plan - Bonus Plan for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
Nippon India Pharma Fund - Direct Plan - Bonus Plan | 1.73 | 3.94 | 5.25 |
As on December 2022
The alpha for Nippon India Pharma Fund - Direct Plan - Bonus Plan is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Nippon India Pharma Fund - Direct Plan - Bonus Plan for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
Nippon India Pharma Fund - Direct Plan - Bonus Plan | 0.94 | 0.93 | 0.88 |
As on December 2022
The Beta for Nippon India Pharma Fund - Direct Plan - Bonus Plan is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Nippon India Pharma Fund - Direct Plan - Bonus Plan for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
Nippon India Pharma Fund - Direct Plan - Bonus Plan | -0.92 | 0.93 | 0.59 |
As on December 2022
The sharpe ratio for Nippon India Pharma Fund - Direct Plan - Bonus Plan is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Nippon India Pharma Fund - Direct Plan - Bonus Plan for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
Nippon India Pharma Fund - Direct Plan - Bonus Plan | 14.66 | 21.07 | 18.71 |
As on December 2022
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 2.08 as on December 2022. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.89 as on December 2022. It tells the consistency of the fund in generating superior risk-adjusted performance
Sailesh Raj Bhan,Kinjal Desai,Akshay Sharma are the fund managers of Nippon India Pharma Fund - Direct Plan - Bonus Plan
The Exit load of Nippon India Pharma Fund - Direct Plan - Bonus Plan is 1%
Mutual Fund execution provided by
Technology facilitation Services provided by Finzoom Investment Advisors Pvt. Ltd. - Advisory unit. SEBI Registered Investment Advisor: INA100012190 | BASL Registration No. 1154 | BSE StarMF Platform code: 24801
Disclaimer: Mutual Fund investments are subject to market risks, read all scheme related documents carefully. Past performance is not indicative of future returns.